Hydroxychloroquine (Plaquenil) and Retinal Toxicity: What Every Patient Should Know
Schedule Today
Who Is at Risk and Why
Not every patient who takes Plaquenil will develop retinal toxicity, but certain factors raise the risk significantly. Knowing your personal risk profile helps your care team set the right screening schedule for you.
The two strongest risk factors are how much Plaquenil you take each day and how long you have been taking it. Patients who take more than 5.0 mg per kilogram of actual body weight per day face a considerably higher risk of toxicity. Duration matters too: the risk is low in the first five years at recommended doses, but rises meaningfully after ten years and approaches nearly 20% after twenty years of continuous use. Keeping the daily dose at or below 5.0 mg/kg is one of the most effective ways to protect the retina.
The kidneys are responsible for clearing Plaquenil from the body. When kidney function is reduced, the drug can build up to higher levels in tissues, including the retina. Patients with kidney disease are at meaningfully higher risk for retinal toxicity and may need more frequent screening than other patients.
Tamoxifen citrate, a medication commonly used to treat breast cancer, significantly increases the risk of Plaquenil retinal toxicity when the two drugs are taken together. Patients taking both medications should be monitored especially closely, and their eye care provider and prescribing physician should coordinate their care carefully.
Several additional factors can further increase retinal risk and should always be disclosed to your eye care provider.
- A daily dose over 400 mg, or over 6.5 mg/kg of ideal body weight in shorter-statured patients
- A total lifetime cumulative dose exceeding 1,000 grams
- Pre-existing retinal or macular disease, which can make the retina more vulnerable to additional damage
Symptoms and Warning Signs
One of the challenges with Plaquenil retinal toxicity is that the early stages often produce no noticeable symptoms at all. By the time a patient notices changes in vision, the damage is often already significant. This is why routine screening, not symptom monitoring, is the foundation of early detection.
In the early stages of Plaquenil retinal toxicity, most patients notice nothing out of the ordinary. Their visual acuity may seem unchanged, and their daily activities may feel completely normal. This silent progression is exactly why imaging and functional testing are necessary even when you feel fine.
As toxicity advances, patients may begin to notice paracentral scotomas, which are small blind spots that appear near the center of vision but not directly at it. These gaps in vision can make reading difficult because letters or words may seem to disappear. Some patients also notice changes in color vision. Most patients, however, do not become aware of these symptoms until the blind spots have grown considerably larger.
In more advanced cases, central visual acuity and the surrounding area of vision become significantly affected. Recognizing faces, reading, and other detail-dependent tasks become increasingly difficult. On examination, a pattern called bull's eye maculopathy, a ring of damaged tissue surrounding the fovea, may be visible. At this stage, the vision loss is typically substantial and cannot be reversed.
Managing Retinal Toxicity: Steps and Decisions
There is currently no treatment that can restore retinal cells damaged by Plaquenil. All management efforts are focused on stopping further damage as early as possible and supporting the patient through any changes in vision.
Once photoreceptors and RPE cells are damaged, they do not regenerate. This reality is why early detection is considered the most important part of managing Plaquenil toxicity. The earlier changes are found, the better the chance of preserving useful vision for the long term.
When screening detects early signs of retinal toxicity, the most important step is to inform the prescribing physician so that stopping the medication or switching to an alternative can be considered. Discontinuing Plaquenil can slow or halt further retinal damage, but some progression may continue for a period after stopping due to the drug's persistence in retinal tissue. This decision should always be made collaboratively between the patient, the prescribing physician, and the eye care provider.
Patients who discontinue Plaquenil due to early toxicity should continue receiving regular retinal examinations. Because the drug can remain bound in the RPE for some time after stopping, retinal changes may continue to appear even after the medication is gone. Ongoing monitoring ensures that any further progression is identified and that appropriate support is provided.
Patients who have developed meaningful vision loss from Plaquenil toxicity can benefit from low vision rehabilitation. A low vision specialist can recommend magnifying tools, lighting adjustments, and high-contrast settings on electronic devices that help patients maintain independence. Adapting your environment and daily routines can make a significant difference in quality of life.
Your Screening Schedule and What to Expect
Following the recommended screening schedule is one of the most important things you can do to protect your vision while taking Plaquenil. Knowing what to expect at each visit makes the process easier and less stressful.
A baseline eye examination should take place within the first year of starting Plaquenil. For patients at low risk, annual screening is recommended starting after five years of use. Patients with elevated risk factors, including kidney disease, tamoxifen use, or higher doses, should discuss beginning annual screening sooner with their eye care provider. Your provider will tailor the schedule to your specific situation.
A typical Plaquenil screening visit includes a dilated eye examination, OCT imaging, and automated visual field testing. Some visits may also include fundus autofluorescence or other specialized testing depending on your individual risk profile. The process is noninvasive and generally takes between one and two hours. Your provider will compare current results to your previous examinations to identify any new changes in retinal structure or function.
Patients can take meaningful steps to reduce their risk and support early detection.
- Take only the prescribed dose and avoid exceeding the recommended amount based on your body weight
- Attend every scheduled screening appointment, even when your vision feels normal
- Tell your eye care provider about any changes in kidney function or new medications, including tamoxifen
- Report new blind spots, reading difficulties, or color vision changes to your provider promptly
Open communication between your prescribing physician and your eye care provider is essential. Keeping all members of your care team informed ensures your screening stays on schedule and that any increase in risk is addressed quickly.
Frequently Asked Questions
Below are answers to questions our patients commonly ask about Plaquenil and retinal toxicity. These are intended to complement, not repeat, the information covered above.
This decision depends on how significant the early findings are and how important Plaquenil is for controlling your autoimmune condition. In some cases, the prescribing physician may reduce the dose rather than stop the medication entirely, particularly if your disease is difficult to manage with alternatives. The decision is always made jointly and weighs the risk of vision loss against the consequences of undertreated autoimmune disease. Your eye care provider and prescribing physician will collaborate to help you make the most informed choice possible.
Prior eye surgery or the need for corrective lenses does not disqualify you from Plaquenil screening, but it is important to disclose these details at your baseline exam. Certain retinal conditions related to high nearsightedness, for example, can produce findings that resemble early toxicity on some tests. Knowing your full eye history helps your provider interpret results accurately and avoid unnecessary concern or missed findings.
Missing a single annual screening is not an emergency, but it should be rescheduled as promptly as possible. Because toxicity can progress silently, gaps in screening reduce the chance of catching changes at their earliest and most manageable stage. If you have been on Plaquenil for more than five years and have not had recent screening, contact your eye care provider to schedule an appointment soon rather than waiting until your next routine visit.
While a general ophthalmologist or optometrist may perform basic eye exams, Plaquenil toxicity screening requires specialized imaging equipment and expertise in interpreting subtle retinal changes. A retina specialist has advanced training in diagnosing and monitoring retinal conditions and has access to the full range of tests recommended for this purpose. Patients with known risk factors or any pre-existing retinal condition should strongly consider seeing a retina specialist for their Plaquenil monitoring.
Paracentral scotomas, the earliest symptom of Plaquenil toxicity, can sometimes be noticed at home by covering one eye and focusing on a central point. If parts of the surrounding area appear blurry, distorted, or missing, that is worth reporting to your provider promptly. Color vision changes or difficulty reading that comes on gradually can also be early signals. You should not wait for your next scheduled appointment if you notice any new or unusual visual symptoms.
That decision belongs to your prescribing physician, who understands your full medical history and the specific demands of managing your autoimmune condition. Your eye care provider can share findings and risk information with your physician, who can then assess whether an alternative immunomodulating therapy is appropriate for your situation. Never stop or change Plaquenil on your own without speaking with your prescribing physician first.
Schedule Your Plaquenil Eye Screening
Protecting your vision while managing your health is something our team takes seriously. Our providers have the specialized expertise and advanced imaging technology needed to detect early retinal changes and guide your care with confidence. If you are taking Plaquenil and have not yet had a baseline exam or are due for your annual screening, we encourage you to reach out and schedule an appointment with us today.